Sfoglia per Autore
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy
2006 L. Losi, G. Luppi, M. Gavioli, F. Iachetta, F. Bertolini, R. D'Amico, G. Jovic, F. Bertoni, A.M. Falchi, P. Conte
Biomarker expression and survival after primary chemotherapy for breast cancer
2007 V. Guarneri, F. Piacentini, G. Jovic, A. Frassoldati, G. Ficarra, S. Giovannelli, M. Maur, F. Borghi, R. Vicini, P.F. Conte
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer
2007 V. Guarneri, A. Frassoldati, F. Piacentini, K. Cagossi, L. Cavanna, A. Michelotti, G. Jovic, S. Giovannelli, G. Ficarra, C. Oliva, P.F. Conte
Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles.
2007 G. Emilia, M. Luppi, P. Zucchini, M. Morselli, L. Potenza, F. Forghieri, F. Volzone, G. Jovic, G. Leonardi, A. Donelli, G. Torelli
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
2007 F. Bertolini,C. Bengala,L. Losi,M. Pagano, F. Iachetta,C. Dealis,G. Jovic,R. Depenni,S. Zironi,A.M. Falchi,G. Luppi,P.F. Conte
Exact method for analysis after single-stage and two-stage phase II cancer clinical trial
2008 G. Jovic
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases : impact on patient management
2008 V. Guarneri, S. Giovannelli, G. Ficarra, S. Bettelli, A. Maiorana, F. Piacentini, E. Barbieri, M.V. Dieci, R. D'Amico, G. Jovic, P.F. Conte
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer : a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)
2008 A. Frassoldati, V. Guarneri, F. Piacentini, G. Jovic, S. Giovannelli, C. Oliva, P.F. Conte
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial)
2008 V. Guarneri, A. Frassoldati, F. Piacentini, G. Jovic, S. Giovannelli, C. Oliva, P.F. Conte
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile